214 related articles for article (PubMed ID: 25768998)
21. BCL2 blockade overcomes MCL1 resistance in multiple myeloma.
Siu KT; Huang C; Panaroni C; Mukaihara K; Fulzele K; Soucy R; Thorburn C; Cidado J; Drew L; Chattopadhyay S; Raje N
Leukemia; 2019 Aug; 33(8):2098-2102. PubMed ID: 30816329
[No Abstract] [Full Text] [Related]
22. Targeting apoptotic pathways to treat lymphoid malignancies.
Roberts AW
Rinsho Ketsueki; 2016; 57(10):2054-2058. PubMed ID: 27795514
[TBL] [Abstract][Full Text] [Related]
23. A BH3 Mimetic for Killing Cancer Cells.
Green DR
Cell; 2016 Jun; 165(7):1560. PubMed ID: 27315468
[TBL] [Abstract][Full Text] [Related]
24. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
Rasmussen PK
Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
[TBL] [Abstract][Full Text] [Related]
25. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
[TBL] [Abstract][Full Text] [Related]
26. Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition.
Bala Tannan N; Manzari MT; Herviou L; Da Silva Ferreira M; Hagen C; Kiguchi H; Manova-Todorova K; Seshan V; de Stanchina E; Heller DA; Younes A
Blood; 2021 Apr; 137(15):2057-2069. PubMed ID: 33067607
[TBL] [Abstract][Full Text] [Related]
27. Bcl-2 inhibition in DLBCL: "the times they are a-changing"?
Vitolo U; Novo M
Blood; 2021 Feb; 137(5):577-579. PubMed ID: 33538802
[No Abstract] [Full Text] [Related]
28. PI3Kδ inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax.
Serrat N; Guerrero-Hernández M; Matas-Céspedes A; Yahiaoui A; Valero JG; Nadeu F; Clot G; Di Re M; Corbera-Bellalta M; Magnano L; Rivas-Delgado A; Enjuanes A; Beà S; Cid MC; Campo E; Montero J; Hodson DJ; López-Guillermo A; Colomer D; Tannheimer S; Pérez-Galán P
Blood Adv; 2020 Sep; 4(17):4217-4231. PubMed ID: 32898249
[TBL] [Abstract][Full Text] [Related]
29. Venetoclax active and safe in non-Hodgkin lymphoma.
Das M
Lancet Oncol; 2017 Mar; 18(3):e136. PubMed ID: 28139404
[No Abstract] [Full Text] [Related]
30. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
[TBL] [Abstract][Full Text] [Related]
31. Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes.
Scholze H; Stephenson RE; Reynolds R; Shah S; Puri R; Butler SD; Trujillo-Alonso V; Teater MR; van Besien H; Gibbs-Curtis D; Ueno H; Parvin S; Letai A; Mathew S; Singh A; Cesarman E; Melnick A; Giulino-Roth L
Blood Adv; 2020 Oct; 4(20):5226-5231. PubMed ID: 33104794
[TBL] [Abstract][Full Text] [Related]
32. Rescue Therapy of Refractory Diffuse Large B-Cell Lymphomas BCL2 with Venetoclax: Case Report.
Sica A; Sagnelli C; Vitiello P; Franco R; Argenziano G; Ciccozzi M; Sagnelli E; Ronchi A
Chemotherapy; 2020; 65(5-6):161-165. PubMed ID: 33477155
[TBL] [Abstract][Full Text] [Related]
33. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
[TBL] [Abstract][Full Text] [Related]
34. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.
Advani A; Coiffier B; Czuczman MS; Dreyling M; Foran J; Gine E; Gisselbrecht C; Ketterer N; Nasta S; Rohatiner A; Schmidt-Wolf IG; Schuler M; Sierra J; Smith MR; Verhoef G; Winter JN; Boni J; Vandendries E; Shapiro M; Fayad L
J Clin Oncol; 2010 Apr; 28(12):2085-93. PubMed ID: 20308665
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression.
Saito B; Shiozawa E; Yamochi-Onizuka T; Adachi D; Nakamaki T; Tomoyasu S; Omine M; Mitsuya T; Takimoto M; Ota H
Pathol Int; 2004 Sep; 54(9):667-74. PubMed ID: 15363034
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy of the lymphomas.
Lacher MJ
Med Times; 1970 May; 98(5):96-102. PubMed ID: 4911076
[No Abstract] [Full Text] [Related]
37. Human Bcl-2 antisense therapy for lymphomas.
Cotter FE; Waters J; Cunningham D
Biochim Biophys Acta; 1999 Dec; 1489(1):97-106. PubMed ID: 10807000
[No Abstract] [Full Text] [Related]
38. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
[TBL] [Abstract][Full Text] [Related]
39. BCL-2 inhibition in follicular lymphoma: can we tip the scales?
Fowler N
Blood; 2020 Dec; 136(23):2598-2600. PubMed ID: 33270856
[No Abstract] [Full Text] [Related]
40. Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14).
Jelinek T; Mihalyova J; Kascak M; Duras J; Popkova T; Benkova K; Richterova P; Plonkova H; Zuchnicka J; Broskevicova L; Huvarova L; Cerna L; Growkova K; Simicek M; Havel M; Gumulec J; Navratil M; Koristek Z; Paiva B; Hajek R
Am J Hematol; 2019 Jan; 94(1):E35-E37. PubMed ID: 30370955
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]